- Use of Pharmacodynamic Principles in the Drug Discovery Process (Michael N.Dudley, Mountain View, CA)
- Lab to Phase II Trial: Use of Microbiology, Animal Model Data and Phase Data for Dose Selection (William A. Craig, Madison, WI)
- The Phase II / III Evaluation: Defining Pharmacodynamics (Including Resistance Emergence) in Patients (George L. Drusano, Albany (NY)
- Defining the Requirements for an Intracellular Antibiotic (Paul M. Tulkens, Brussels, Belgium)
- Defining the Basic Requirements for Antiviral Agents: Beyond the a-cellular Systems (Lieve Naesens, Leuven, Belgium)
- The Ultimate Intracellular Pathogen - HIV and Delineation of Pharmacodynamics in an In Vitro System (John Bilello, Albany, NY)
- Cell Culture Models for the Prospective Assessment of Toxicity (Françoise Van Bambeke, Brussels, Belgium)
- Animal Models toDefine the Least Toxic Regimens (Denis Beauchamp, Ste Foy, Qué.)
- Toxicity of Once Daily Aminoglycosides in a Randomized Double Blind Trial (Michael Rybak, Detroit, WI)
- New Mathematical approaches for Pharmacodynamically Based Delineation of Dose (Johan W. Mouton, Nijmegen, The Netherlands)
- Fungi: The Pharmacodynamically Ignored Pathogens (Arnold Louie, Albany, NY)
- Limitations of Animal Models for Predicting Efficacy and Defining Dose (James Leggett, Portland, OR)
Round table:
Pharmacodynamics and the
DrugDevelopment Process: The View from Academia, Industry and the
Regulatory Agencies
Phil Colangelo (FDA, USA),
Sousan Altie (FDA, USA), Mike Dudley (Microcide Pharm., CA), Rodger Echols
(Bristol-Myers Squibb, NJ), George Drusano (Albany Med. Ctr, NY), William
Craig (Univ. of Wisconsin, WI)
